Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Journal of Autism and Developmental Disorders 3/2013

01-03-2013 | Brief Report

Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials

Auteurs: Lawrence Scahill, Victoria Hallett, Michael G. Aman, Christopher J. McDougle, L. Eugene Arnold, James T. McCracken, Elaine Tierney, Yanhong Deng, James Dziura, Benedetto Vitiello, the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network)

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 3/2013

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training. After 8 weeks of treatment, all active treatments were superior to placebo (effect sizes ranging from 0.42 to 0.65). The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
go back to reference Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1143–1154. PubMedCrossRef Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1143–1154. PubMedCrossRef
go back to reference Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency, 89, 492–502. PubMed Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency, 89, 492–502. PubMed
go back to reference Brown, E. C., Aman, M. G., & Havercamp, S. M. (2002). Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist—Community for young people in special education. Research in Developmental Disabilities, 23, 45–60. PubMedCrossRef Brown, E. C., Aman, M. G., & Havercamp, S. M. (2002). Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist—Community for young people in special education. Research in Developmental Disabilities, 23, 45–60. PubMedCrossRef
go back to reference Carter, A. S., Volkmar, F. R., Sparrow, S. S., et al. (1998). The Vineland Adaptive Behavior Scales: Supplementary norms for individuals with autism. Journal of Autism and Developmental Disorders, 28(4), 287–302. PubMedCrossRef Carter, A. S., Volkmar, F. R., Sparrow, S. S., et al. (1998). The Vineland Adaptive Behavior Scales: Supplementary norms for individuals with autism. Journal of Autism and Developmental Disorders, 28(4), 287–302. PubMedCrossRef
go back to reference Centers for Disease Control and Prevention. (2012). Prevalence of Autism Spectrum Disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. Morbidity Mortality Weekly Report, 61(3), 2–19. Centers for Disease Control and Prevention. (2012). Prevalence of Autism Spectrum Disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. Morbidity Mortality Weekly Report, 61(3), 2–19.
go back to reference Dolen, G., Carpenter, R. L., Ocain, T. D., & Bear, M. F. (2010). Mechanism-based approaches to treating fragile X. Pharmacology & Therapeutics, 127(2010), 78–93. CrossRef Dolen, G., Carpenter, R. L., Ocain, T. D., & Bear, M. F. (2010). Mechanism-based approaches to treating fragile X. Pharmacology & Therapeutics, 127(2010), 78–93. CrossRef
go back to reference Gadow, K. D., DeVincent, C., & Schneider, J. (2008). Predictors of psychiatric symptoms in children with an Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 38, 1710–1720. PubMedCrossRef Gadow, K. D., DeVincent, C., & Schneider, J. (2008). Predictors of psychiatric symptoms in children with an Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 38, 1710–1720. PubMedCrossRef
go back to reference Guy, W. (1976). Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health. Guy, W. (1976). Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health.
go back to reference Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., et al. (2011). Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Science Translational Medicine, 3(64), 64ra1. PubMedCrossRef Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., et al. (2011). Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Science Translational Medicine, 3(64), 64ra1. PubMedCrossRef
go back to reference King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behaviour: citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590. PubMedCrossRef King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behaviour: citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590. PubMedCrossRef
go back to reference Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagonostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24, 659–685. PubMedCrossRef Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagonostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24, 659–685. PubMedCrossRef
go back to reference Lecavalier, L. (2006). Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders, 36, 1101–1114. PubMedCrossRef Lecavalier, L. (2006). Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders, 36, 1101–1114. PubMedCrossRef
go back to reference Levy, S. E., Mandell, D. S., & Schultz, R. T. (2007). Autism. Lancet, 374(9701), 1627–1638 (Erratum appears in Lancet. 2011 Oct 29;378(9802):1546). Levy, S. E., Mandell, D. S., & Schultz, R. T. (2007). Autism. Lancet, 374(9701), 1627–1638 (Erratum appears in Lancet. 2011 Oct 29;378(9802):1546).
go back to reference Marcus, R. N., Owen, R., Kamen, L., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119. PubMedCrossRef Marcus, R. N., Owen, R., Kamen, L., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119. PubMedCrossRef
go back to reference O’ Roak, B. J., & State, M. W. (2008). Autism genetics: Strategies, challenges, and opportunities. Autism Research, 1(1), 4–17. PubMedCrossRef O’ Roak, B. J., & State, M. W. (2008). Autism genetics: Strategies, challenges, and opportunities. Autism Research, 1(1), 4–17. PubMedCrossRef
go back to reference Owen, R., Sikich, L., Marcus, R., et al. (2009). A multicenter, double-blind, randomized, placebo controlled, flexible-dose, parallel-group study of aripiprazole in the treatment of irritability in children and adolescents (6–17 years) with autistic disorder. Pediatrics, 124, 1533–1540. PubMedCrossRef Owen, R., Sikich, L., Marcus, R., et al. (2009). A multicenter, double-blind, randomized, placebo controlled, flexible-dose, parallel-group study of aripiprazole in the treatment of irritability in children and adolescents (6–17 years) with autistic disorder. Pediatrics, 124, 1533–1540. PubMedCrossRef
go back to reference Posey, D. J., Erickson, C. A., & McDougle, C. J. (2008). Developing drugs for core social and communication impairment in autism. Child & Adolescent Psychiatric Clinics of North America, 17(4), 787–801. CrossRef Posey, D. J., Erickson, C. A., & McDougle, C. J. (2008). Developing drugs for core social and communication impairment in autism. Child & Adolescent Psychiatric Clinics of North America, 17(4), 787–801. CrossRef
go back to reference Research Units on Pediatric Psychopharmacology (RUPP) Autism Network (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274.
go back to reference Robinson, E. B., Koenen, K. C., McCormick, M. C., Munir, K., Hallett, V., Happe, F., et al. (2011). Evidence that autistic traits show the same etiology in the general population and at the quantitative extremes (5%, 2.5%, and 1%). Archives of General Psychiatry, 68(11), 1113–1121. PubMedCrossRef Robinson, E. B., Koenen, K. C., McCormick, M. C., Munir, K., Hallett, V., Happe, F., et al. (2011). Evidence that autistic traits show the same etiology in the general population and at the quantitative extremes (5%, 2.5%, and 1%). Archives of General Psychiatry, 68(11), 1113–1121. PubMedCrossRef
go back to reference RUPP Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. NEJM, 347(5), 314–321. CrossRef RUPP Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. NEJM, 347(5), 314–321. CrossRef
go back to reference Scahill, L., McDougle, C. J., Aman, M. G., Johnson, C., Handen, B., Bearss, K., et al. (2012). Effects of risperidone and parent training on adaptive functioning in children with a pervasive developmental disorders and serious behavioral problems. Journal of the American Academy of Child and Adolescent Psychiatry, 51(2), 136–146. PubMedCrossRef Scahill, L., McDougle, C. J., Aman, M. G., Johnson, C., Handen, B., Bearss, K., et al. (2012). Effects of risperidone and parent training on adaptive functioning in children with a pervasive developmental disorders and serious behavioral problems. Journal of the American Academy of Child and Adolescent Psychiatry, 51(2), 136–146. PubMedCrossRef
go back to reference Shea, S., Turgay, A., Carrol, A., et al. (2004). Risperidone in the treatment of disruptive behavioural symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634–e641. PubMedCrossRef Shea, S., Turgay, A., Carrol, A., et al. (2004). Risperidone in the treatment of disruptive behavioural symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634–e641. PubMedCrossRef
go back to reference Sparrow, S. S., Balla, D. A., & Cicchetti, D. V. (1984). Vineland adaptive behavior scales. Circle Pines, MN: American Guidance Service. Sparrow, S. S., Balla, D. A., & Cicchetti, D. V. (1984). Vineland adaptive behavior scales. Circle Pines, MN: American Guidance Service.
go back to reference Sukhodolsky, D. G., Scahill, L., Gadow, K. D., Arnold, L. E., Aman, M. G.., McDougle, C. J., et al. (2008). Parent-rated anxiety symptoms in children with pervasive developmental disorders: Frequency and association with core autism symptoms and cognitive functioning. Journal of Abnormal Child Psychology, 36(1), 117–128. PubMedCrossRef Sukhodolsky, D. G., Scahill, L., Gadow, K. D., Arnold, L. E., Aman, M. G.., McDougle, C. J., et al. (2008). Parent-rated anxiety symptoms in children with pervasive developmental disorders: Frequency and association with core autism symptoms and cognitive functioning. Journal of Abnormal Child Psychology, 36(1), 117–128. PubMedCrossRef
go back to reference US Food and Drug Administration. (2006). Guidance for industry: Patient- reported outcome measures: Use in medical product development to support labeling claims. Available from: ttp:// www.​Fda.​Gov/​Cder/​Guidance/​5460dft.​Pdf [Accessed May 4, 2007]. Federal Register: February 3, 2006, Vol. 71. Number (23) Docket no. 2006D-0044. US Food and Drug Administration. (2006). Guidance for industry: Patient- reported outcome measures: Use in medical product development to support labeling claims. Available from: ttp:// www.​Fda.​Gov/​Cder/​Guidance/​5460dft.​Pdf [Accessed May 4, 2007]. Federal Register: February 3, 2006, Vol. 71. Number (23) Docket no. 2006D-0044.
go back to reference Veenstra-VanderWeele, J., King, B., Erickson, C., Ginsberg, L., Melman, R., Scahill, L., et al. (2011). An open label trial of arbaclofen in autism spectrum disorder shows improvements in multiple symptom domains. Poster presentation at NCDEU. Spring, 2011. Veenstra-VanderWeele, J., King, B., Erickson, C., Ginsberg, L., Melman, R., Scahill, L., et al. (2011). An open label trial of arbaclofen in autism spectrum disorder shows improvements in multiple symptom domains. Poster presentation at NCDEU. Spring, 2011.
Metagegevens
Titel
Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials
Auteurs
Lawrence Scahill
Victoria Hallett
Michael G. Aman
Christopher J. McDougle
L. Eugene Arnold
James T. McCracken
Elaine Tierney
Yanhong Deng
James Dziura
Benedetto Vitiello
the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network)
Publicatiedatum
01-03-2013
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 3/2013
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-012-1689-3